RT Journal Article
SR Electronic
T1 Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: A retrospective study from Burkina Faso and simulated case analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.04.20119784
DO 10.1101/2020.06.04.20119784
A1 Laura Skrip
A1 Karim Derra
A1 Mikaila Kaboré
A1 Navideh Noori
A1 Adama Gansané
A1 Innocent Valéa
A1 Halidou Tinto
A1 Bicaba W. Brice
A1 Mollie Van Gordon
A1 Brittany Hagedorn
A1 Hervé Hien
A1 Benjamin M. Althouse
A1 Edward A. Wenger
A1 André Lin Ouédraogo
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/2020.06.04.20119784.abstract
AB Background Absolute numbers of COVID-19 cases and deaths reported to date in the sub-Saharan Africa (SSA) region have been significantly lower than those across the Americas, Asia, and Europe. As a result, there has been limited information about the demographic and clinical characteristics of deceased cases in the region, as well as the impacts of different case management strategies.Methods Data from deceased cases reported across SSA through May 10, 2020 and from hospitalized cases in Burkina Faso through April 15, 2020 were analyzed. Demographic, epidemiological, and clinical information on deceased cases in SSA was derived through a line-list of publicly available information and, for cases in Burkina Faso, from aggregate records at the Center Hospitalier Universitaire de Tengandogo in Ouagadougou. A synthetic case population was derived probabilistically using distributions of age, sex, and underlying conditions from populations of West African countries to assess individual risk factors and treatment effect sizes. Logistic regression analysis was conducted to evaluate the adjusted odds of survival for patients receiving oxygen therapy or convalescent plasma, based on therapeutic effectiveness observed for other respiratory illnesses.Results Across SSA, deceased cases for which demographic data are available have been predominantly male (63/103, 61.2%) and over 50 years of age (59/75, 78.7%). In Burkina Faso, specifically, the majority of deceased cases either did not seek care at all or were hospitalized for a single day (59.4%, 19/32); hypertension and diabetes were often reported as underlying conditions. After adjustment for sex, age, and underlying conditions in the synthetic case population, the odds of mortality for cases not receiving oxygen therapy was significantly higher than those receiving oxygen, such as due to disruptions to standard care (OR: 2.07; 95% CI: 1.56 – 2.75). Cases receiving convalescent plasma had 50% reduced odds of mortality than those who did not (95% CI: 0.24 – 0.93).Conclusion Investment in sustainable production and maintenance of supplies for oxygen therapy, along with messaging around early and appropriate use for healthcare providers, caregivers, and patients could reduce COVID-19 deaths in SSA. Further investigation into convalescent plasma is warranted, as data on its effectiveness specifically in treating COVID-19 becomes available. The success of supportive or curative clinical interventions will depend on earlier treatment seeking, such that community engagement and risk communication will be critical components of the response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLAS, BH, BA, EAW and ALO designed the study. LAS, NN, MVG, KD, MK, AG, IV, HT, BWB, and HH collected data for the linelist or at the Center Hospitalier Universitaire de Tengandogo in Ouagadougou. ALO conducted the data simulation. LAS and ALO conducted the data analysis. LAS and ALO wrote the first draft of the manuscript. All authors contributed intellectually and made contributions to the manuscript text.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data presented here were derived from publicly available sources or provided by CHU as part of the national epidemic response program. The data from CHU were reported in aggregate, as frequency distributions across 10-year age bins, by sex, or length-of-stay in hospitals. The study was therefore not subject to review by an ethics board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are presented in tables and figures within the text.